--- title: "What I'm Hearing on Q2 Earnings Surprises and Strategic Overhauls Across Niche Markets" type: "News" locale: "en" url: "https://longbridge.com/en/news/294796340.md" description: "This week's updates reveal significant momentum for specialty leaders. Chewy and Wix posted solid profitability metrics, while Hesai and Momentus locked in crucial commercial milestones heading into late 2026." datetime: "2026-08-04T09:17:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294796340.md) - [en](https://longbridge.com/en/news/294796340.md) - [zh-HK](https://longbridge.com/zh-HK/news/294796340.md) generator: "portal-rs" --- # What I'm Hearing on Q2 Earnings Surprises and Strategic Overhauls Across Niche Markets Despite the macroeconomic noise sweeping through the broader markets recently, I'm told that several companies across diverse verticals are pushing through with some of their most significant operational overhauls and expansions of the year. From consumer retail resilience to breakthrough biotech catalysts, the latest round of corporate disclosures suggests underlying strength heading into the fall. ### Chewy (CHWY.US) The online pet supply giant is proving its business model has legs, recently reporting record profitability and showcasing resilient stock performance year-to-date. In the first quarter of 2026, Chewy’s net sales climbed 7.7% to USD 3.36 billion with nearly 200,000 net customer additions. Perhaps more intriguingly, I'm told their April acquisition of Modern Animal marks a deliberate pivot into a fully integrated healthcare ecosystem—a move that could define the company's trajectory later this year. ### Wix.com (WXXWY.US) Wix continues to expand its footprint in the SaaS arena, with its shares tracking favorably against software peers recently. According to the company's Q2 2026 results, revenue grew 15% year-over-year to USD 563.1 million. The rollout of a new HIPAA-compliant solution signals a serious attempt to capture the US healthcare provider market. CEO Avishai Abrahami’s optimistic commentary regarding the Base44 margin targets suggests further upside before the next earnings cycle. ### Hesai Group (HESAY.US) On the automotive tech front, LiDAR market leader Hesai is quietly locking in future revenue. According to people familiar with the matter, the company's ETX ultra-long-range platform has secured a new design win with Great Wall Motor, slated for mass production by late 2026. This commercial validation serves as a critical backdrop as investors await their Q2 earnings call scheduled for August 18. ### Edison International (EIX.US) Edison International is undertaking its own strategic repositioning. The utility holding company just offloaded its clean energy consulting firm, Trio, at a USD 23 million loss, refocusing entirely on a massive USD 38 billion to USD 41 billion grid investment plan through 2030. I'm hearing that management has issued a stark warning: without decisive action from California lawmakers by the end of August, the state's investor-owned utilities could face imminent credit rating downgrades. ### Kodiak Sciences (KOD.US) Wall Street is taking a closer look at clinical-stage biopharma Kodiak Sciences. Following positive Phase 3 results for its diabetic retinopathy drug Zenkuda earlier in 2026, JPMorgan recently bumped its price target up to USD 66 while maintaining an overweight rating. Expect their upcoming clinical data presentations to be closely scrutinized by institutional investors. ### Nuvectis Pharma (NVTX.US) & Nuwe Corp (NUWE.US) It's been a busy quarter for medical tech and precision medicine. Nuvectis Pharma (NVTX.US) got a major boost in late July when its partner-developed Ciprocopan scored regulatory approval in China. Meanwhile, Nuwe Corp (NUWE.US), which specializes in fluid overload solutions, pulled off a USD 3.4 million direct offering on July 31. The company anticipates double-digit preliminary revenue growth for Q2 2026, driven by expanding pediatric installations. ### Momentus (MNTS.US) Space infrastructure firm Momentus is logging steady operational wins. In late July, the company confirmed that its Vigoride 7 spacecraft executed a clean orbital maneuver, while its Vigoride 8 vehicle passed critical design reviews for a 2027 launch. Backed by a new commercial contract secured in June, Momentus is steadily validating its in-orbit service capabilities. ### Also - **Estée Lauder (EL.US)**: With consumer discretionary spending fluctuating, the beauty conglomerate's near-term strategic adjustments remain a focal point for analysts seeking clarity on a turnaround heading into Q4. - **RAMZ (RAMZ.US)**: I'm told the market is keeping a wait-and-see approach on this ticker, as no significant operational updates or public financial data have surfaced in recent weeks. *This article does not constitute investment advice.* ### Related Stocks - [CHWY.US](https://longbridge.com/en/quote/CHWY.US.md) - [MNTS.US](https://longbridge.com/en/quote/MNTS.US.md) - [HESAY.US](https://longbridge.com/en/quote/HESAY.US.md) - [EL.US](https://longbridge.com/en/quote/EL.US.md) - [EIX.US](https://longbridge.com/en/quote/EIX.US.md) - [KOD.US](https://longbridge.com/en/quote/KOD.US.md) - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) - [NUWE.US](https://longbridge.com/en/quote/NUWE.US.md) ## Related News & Research - [Estee Lauder declares $0.35 dividend](https://longbridge.com/en/news/296444619.md) - [Estée Lauder (EL) Reports Earnings Tomorrow: What To Expect](https://longbridge.com/en/news/296169918.md) - [Estée Lauder stock surges as earnings show growth plan is working](https://longbridge.com/en/news/296361358.md) - [Estée Lauder Analysts Boost Their Forecasts After Better-Than-Expected Q2 Results](https://longbridge.com/en/news/296514750.md) - [Estée Lauder Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call](https://longbridge.com/en/news/296307779.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**